Why the study?
Does SA446 inhibit converting enzyme activity and reduce blood pressure in preclinical models?
Population
Preclinical models including semi-purified rabbit lung converting enzyme, isolated guinea pig ileum, rats…
Comparison
SA446 administered in vitro, intravenously, or… vs Captopril and baseline/control responses
Design
Preclinical
Authors
Loading...
Supports advancing SA446 to human studies; leaves open clinical efficacy and safety in hypertension.
Does SA446 inhibit converting enzyme activity and reduce blood pressure in preclinical models?
SA446 is a potent, orally active converting enzyme inhibitor with significant antihypertensive effects in hypertensive rat models.
Iso et al. (1981) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: